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Abstract
Familial hematuria (FH) is explained by at least four different genes (see below). About 50% of patients develop late
proteinuria and chronic kidney disease (CKD). We hypothesized that MYH9/APOL1, two closely linked genes associated with
CKD, may be associated with adverse progression in FH. Our study included 102 thin basement membrane nephropathy
(TBMN) patients with three known COL4A3/COL4A4 mutations (cohort A), 83 CFHR5/C3 glomerulopathy patients (cohort B)
with a single CFHR5 mutation and 15 Alport syndrome patients (cohort C) with two known COL4A5 mild mutations, who
were categorized as ‘‘Mild’’ (controls) or ‘‘Severe’’ (cases), based on renal manifestations. E1 and S1 MYH9 haplotypes and
variant rs11089788 were analyzed for association with disease phenotype. Evidence for association with ‘‘Severe’’
progression in CFHR5 nephropathy was found with MYH9 variant rs11089788 and was confirmed in an independent FH
cohort, D (cumulative p value = 0.001, odds ratio = 3.06, recessive model). No association was found with APOL1 gene.
Quantitative Real time PCR did not reveal any functional significance for the rs11089788 risk allele. Our results derive
additional evidence supporting previous reports according to which MYH9 is an important gene per se, predisposing to CKD,
suggesting its usefulness as a prognostic marker for young hematuric patients.
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Introduction
The differential diagnosis in 2012 for familial hematuria (FH)
includes mostly the COL4A3/A4 heterozygous carriers that exhibit
thin basement membrane nephropathy (TBMN) with lifelong
microscopic hematuria [1–5] and a newly described disease,
CFHR5 nephropathy, with isolated C3 mesangial deposits [6,7].
Other still unknown causes may exist.
Heterozygous mutations in the COL4A3/COL4A4 genes are said
to account for up to 40–50% of families with TBMN [1–5].
CFHR5 nephropathy is also an autosomal dominant disease with
an up to now unknown prevalence, although it is highly prevalent
in Cyprus [6,7]. We and others demonstrated that more than 50%
of these patients develop added proteinuria and chronic kidney
disease (CKD) after the age of 30 and with a broad phenotypic
spectrum [8–10]. Interestingly, X-linked Alport syndrome cases
(male patients) with mild mutations in the COL4A5 gene, often
present as phenocopies of TBMN, with a wide spectrum of
phenotypes [11–17]. We hypothesize that this great phenotypic
heterogeneity is largely due to modifier genes [10].
Studies in animal models for TBMN and Alport syndrome
support the existence of genetic loci that influence disease
progression [18,19]. In humans, studies by Tonna et al (2008)
and Voskarides et al (2012) provide evidence that NPHS2-R229Q
predisposes to proteinuria in TBMN [20,21]. Additionally,
Papagregoriou et al (2012) investigated potential microRNAs’
target sites in hematuric patients and found that a miR-1207-5p
binding site variant abolishes regulation of HBEGF and is
associated with disease severity in CFHR5 nephropathy [22].
In this study, we took advantage of the extended founder effects
we have observed among the Greek-Cypriot population, to
investigate whether genetic polymorphisms of the MYH9/APOL1
region can act as modifiers for the FH phenotype. Genome-wide
association studies (GWAS) have identified MYH9 (Myosin Heavy
Chain 9) and its closely linked gene APOL1, as major susceptibility
genes predisposing towards end stage kidney disease (ESKD), in
various types of renal diseases (idiopathic focal segmental
glomerulosclerosis, HIV-associated nephropathy, hypertensive
nephrosclerosis, diabetic nephropathy, IgA nephropathy progres-
sion), in African-Americans, European-Americans, Europeans,
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e57925
Hispanic-Americans and Chinese [23–27]. For the present work
our cohorts included patients with a monogenic primary form of
FH, TBMN, Alport Syndrome and CFHR5 nephropathy. Our
results demonstrate a likely contribution of MYH9 variant
rs11089788 in the progression of CKD when co-inherited with
CFHR5 nephropathy, but cast doubt on the recently alleged
association with variation in the APOL1 gene that is closely linked
to MYH9.
Materials and Methods
Study Cohorts - Clinical Assessment and Study Outcomes
The study cohorts are presented in Table 1. Patients of all four
cohorts were categorized as having ‘‘Mild’’ or ‘‘Severe’’ disease.
Our main cohorts include 102 adult TBMN patients, 83 adult
CFHR5 patients and 15 Alport syndrome patients. These cohorts
are unique worldwide because they include a large number of
patients with common mutations due to founder effects. Among
102 TBMN patients, 77 carry mutation COL4A3-p.G1334 and 19
carry mutation COL4A3-p.G871C. All 83 CFHR5 patients carry
the same exon 2–3 duplication. This situation offers an advantage
as regards reduced genomic background complexity based on
common ethnicity, thereby facilitating the search for genetic
modifiers in relatively smaller cohorts. Since young individuals
with apparently mild disease could develop severe disease when
older, we excluded young patients without evidence of severe
disease (Table 1). Mild disease was characterized by the presence
of only microscopic hematuria and up to low grade proteinuria,
repeatedly under 300 mg/day and no CKD. ‘‘Severe’’ disease was
characterized by hematuria plus proteinuria $500 mg/day, or
hematuria plus proteinuria plus CKD, or ESKD (Table 1). CKD
was defined as an elevated serum creatinine over 1.5 mg/dL.
Patients with borderline proteinuria and another concomitant
renal disease (e.g., over five years of diabetes, vesicoureteral reflux
etc), or severe patients at the extreme of body weight (outside 62
SD of the cohort mean) were excluded. For Alport syndrome
patients, disease severity is defined by most researchers according
to age at ESKD, so the severe group included patients that
reached ESKD below the age of 40 years. Cohort D was
genotyped for replication purposes, including FH patients not
genetically studied yet. The study was approved by the Cyprus
National Bioethics Committee and participants gave their signed
informed consent, unless they were included anonymously after
testing for purely diagnostic purposes.
Single Nucleotide Polymorphisms (SNPs) genotyping –
Haplotype analysis
We genotyped MYH9 SNPs that were previously shown to be
strongly associated with renal failure in Caucasian populations
(Table 2; it includes information on the PCR-RFLP genotyping
assays): two lying on the E1 risk haplotype (rs4821481 and
rs4821480), one lying on the S1 risk haplotype (rs2413396) and the
rs11089788 variant that is found in the 59-end of MYH9 (IVS3 -
5801C/A) – identified by a meta-analysis study – associated with
serum creatinine levels in three Caucasian populations (Table 2).
DNA samples from 15 patients (six from cohort A, five from
cohort B and four from cohort C), representing all three
rs11089788 genotypes, were selected for PCR amplification
(primers available on request) and DNA re-sequencing (in ABI
PRISMTM 3130) of the last exon of APOL1, where most of non-
synonymous SNPs are located, according to electronic databases
(www.ensemble.org). Three of the five non-synonymous SNPs
detected, were genotyped in cohorts A, B and D. Haplotype
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analysis was performed by Haploview software (http://www.
broad.mit.edu/mpg/haploview/).
Statistical analysis
Genotypic statistical analysis and odds ratios calculations were
performed by SPSS v.13 (IBM, USA). Both dominant and
recessive models of inheritance were tested for significance where
this was possible. P values were calculated by Pearson Chi-Square
test. Fisher’s Exact Test (2-sided) was used where genotype values
less than 10 existed. The significance level, alpha, was set to 0.05.
We decided to genotype the entire cohort B (it includes males and
females with CFHR5 nephropathy), only for SNPs that would give
a p value close to 0.1 for cohort B1 (B1 are only the males with
CFHR5 nephropathy; mostly males proceed to CKD in this type
of FH).
Real Time PCR
mRNA was isolated from peripheral blood leukocytes using the
QIAamp RNA Blood Mini Kit (Qiagen, Germany) from: three
male healthy volunteers genotyped as CC for rs11089788, three
male healthy volunteers genotyped as AA for rs11089788 and
three male ‘‘severe’’ hematuric patients genotyped as CC for
rs11089788. RNA integrity and concentration were assessed by gel
electrophoresis and spectrophotometrically (Nanodrop technolo-
gies), respectively. 200 ng of total RNA from each sample was
reverse transcribed (ProtoScriptTM by New England Biolabs, UK).
The quantitative Real-Time PCR (qRT-PCR) amplifications were
performed in duplicate on the LightCyclerH system (Roche
Diagnostics and Applied Sciences) using SYBR Green (Applied
Biosystems, California, USA) in a reaction volume of 20 ml and
primers according to Liang et al (2011) [28]. Relative quantifica-
tion analysis was carried out on the LightCyclerH Software 4.1.
The endogenous reference gene GAPDH was used for normalisa-
tion of the results. Statistical significance was checked by
independent t-test, through the SPSS v.13 package (IBM, USA).
Results
CC genotype of MYH9 rs11089788 confers significant risk
for proteinuria and CKD
None of the analyzed MYH9 SNPs was significantly associated
with phenotypes in any of our initial cohorts. In accordance with
previous publications, MYH9 rs4821480 was found to be in
complete linkage disequilibrium (LD) withMYH9 rs4821481, after
genotyping 85 samples of cohort A; thus it was not genotyped any
further. MYH9 rs2413396 was found in partial LD with MYH9
rs4821481 (see frequencies in Table 3, LD value was not
calculated). MYH9 rs11089788 gave a p value close to 0.1 in
cohort B1 (Table 4). Hence, cohort B (B=B1 plus the female
patients, see Methods) and D were analyzed only for MYH9
rs11089788. For cohort B, MYH9 rs11089788 gave a p-value of
0.015 (OR=3.18) under a recessive model. Cohort D replicated
the significance for MYH9 rs11089788 (p = 0.024) under a
recessive model of inheritance (Table 5). The significance was
highly increased for the sum of cohorts B+D for MYH9
rs11089788 (p = 0.001 and OR=3.06, see Table 5).
Non-synonymous SNPs found on the last exon of APOL1
Re-sequencing of the last APOL1 exon revealed five non-
synonymous SNPs: p.E149K (rs2239785), p.M227I (rs136175),
p.R254K (rs136176), p.G270D (rs73403889) and p.D336N
(rs16996616). Those SNPs are not among the published ones to
be associated with CKD [29,30]. APOL1 p.E149K, p.M227I and
p.R254K [all reported with significant frequency only in
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Caucasian samples (http://hapmap.ncbi.nlm.nih.gov/)] were
genotyped for the cohorts A, B and D. No significant association
was observed (results not shown). All three APOL1 SNPs were in
complete LD, constructing a haplotype block (results compatible
with HapMap data), but they were not linked with rs11089788
(Figure 1).
Expression of MYH9 in rs11089788 ‘‘CC’’ and ‘‘AA’’
patients
No statistical significance was observed when comparing the
means of the blood mRNA values among the genotypic groups,
(see Methods, results not shown) despite that there was a trend for
an increase of the CCs over the AAs.
Discussion
Genotype CC of rs11089788, located on the 59-end of MYH9,
was found to be significantly associated with bad progression in
FH in two different cohorts. No significant association was
observed for SNPs representing E1 kai S1 haplotypes. This may
be expected as these haplotypes were mainly associated with renal
failure in populations out of Europe [23,24]. On the other hand,
MYH9 rs11089788 was previously associated with high serum
creatinine levels in Europeans [25] and with progression of IgA
nephropathy in Chinese [27]. CFHR5 nephropathy and IgA
nephropathy possibly share common pathophysiology features due
to their immune origin. Pending confirmation with other studies,
our study suggests that rs11089788 is a negative prognostic factor
in CFHR5 nephropathy and possibly in other glomerular
hematuric diseases. This result was confirmed in a second cohort
(D), including hematuric patients of various etiologies. Considering
the two cohorts together, the results show that a hematuric patient
with the CC genotype (recessive model) has a 3.06-fold increased
likelihood (p = 0.001) for proteinuria and renal failure (Table 5).
This enables us to speculate that certain FH types may share
common risk factors as regards disease progression.
Table 4. Genotype associations for the three MYH9 variants genotyped in this study.
Variant p value OR (95% CI) p-value OR (95% CI)
MYH9 rs4821481 TT+TC vs CC TT vs TC+CC
Patients cohort A 0.184* ** 0.572 0.79 (0.34, 1.80)
Patients cohort B1 - - 1.000* 1.06 (0.16, 7.06)
Patients cohort C - - 0.516* **
Sum (A+B1+C) 0.205* ** 0.487 0.78 (0.39, 1.58)
MYH9 rs2413396 TT+TC vs CC TT vs TC+CC
Patients cohort A 1.000* 1.54 (0.14, 17.50) 0.825 1.10 (0.48, 2.50)
Patients cohort B1 - - 0.716* 1.52 (0.33, 7.04)
Patients cohort C - - 0.516* **
Sum (A+B1+C) 1.000* 1.68 (0.15, 18.88) 0.785 1.10 (0.56, 2.17)
MYH9 rs11089788 AA+AC vs CC AA vs AC+CC
Patients cohort A 0.639* 1.36 (0.53, 3.47) 0.509 1.34 (0.56, 3.18)
Patients cohort B1 0.126* 3.00 (0.79, 11.45) 0.133* 3.69 (0.79, 17.25)
Patients cohort B 0.015 3.18 (1.24, 8.17) 0.016* 4.85 (1.28, 18.36)
Patients cohort C 0.604* 0.40 (0.01, 5.15) 0.235* 0.125 (0.01, 1.72)
Sum (A+B+C) 0.129 1.61 (0.87, 2.98) 0.131 1.63 (0.86, 3.09)
P-values were calculated by Pearson Chi-Square test. The whole CFHR5 cohort (B) was genotyped only for MYH9 rs11089788, the only SNP that gave p-value close to 0.1
for the male CFHR5 patients (B1).
*P-values calculated by Fisher’s Exact Test (2-sided) due to existence of genotypes values less than 10.
**Odds ratio (OR) cannot be estimated due to zero genotypic values in the ‘‘Severe’’ category.
doi:10.1371/journal.pone.0057925.t004
Table 5. MYH9 rs11089788 statistical analysis for a replicate cohort (D) and for the sum of cohorts B and D, that gave statistical
significance.
MYH9 rs11089788 P value, Odds ratio P value, Odds ratio
Cohort n AA AC CC AA+AC vs CC AA vs AC+CC
D – ‘‘Mild’’ 33 7 (21%) 18 (55%) 8 (24%) P = 0.024, OR = 3.52 (1.24, 9.97) P = 0.765, OR = 1.26 (0.37, 4.23)
D – ‘‘Severe’’ 34 6 (18%) 10 (29%) 18 (53%)
B+D – ‘‘Mild’’ 83 23 (28%) 40 (48%) 20 (24%) P=0.001, OR=3.06 (1.54, 6.10) P = 0.049, OR = 2.26 (0.99, 5.16)
B+D – ‘‘Severe’’ 69 10 (15%) 25 (36%) 34 (49%)
Patients in cohort D belong to families that segregate microscopic hematuria but no known mutation has been found in any of the genes COL4A3, COL4A4, or CFHR5, so
far.
doi:10.1371/journal.pone.0057925.t005
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It is useful to underline that for certain types of FH, gender is an
important cofounder in the disease progression in association with
the modifier genes. In this study, difference in gender percentages
is significant for cohort B (CFHR5 patients) and cohort D. In a
previous publication we discuss in detail the high risk of male
CFHR5 patients for progression to renal failure, comparing also
the survival rates of renal function in the two genders [6,17]. All in
all however, in accordance with the previous literature, the
significance we describe here is still valid when taking into
consideration the gender.
Recent studies give evidence that three coding SNPs on the last
exon of APOL1 gene, lying on extended haplotypes with theMYH9
SNPs (haplotypes E1, F1 and S1), may be the actual cause for
predisposition to renal failure. On the other hand, O’Seaghdha et
al (2011) found association of rs4821480 with CKD in European-
Americans [31], but did not find an association with any of the
APOL1 SNPs reported by Genovese et al (2010) and Tzur et al
(2010), suggesting that variation in APOL1 may not be the
complete explanation [29,30]. We screened the last exon of
APOL1, but the identified SNPs were not in LD with either of the
two alleles of rs11089788, despite a strong LD existing between
them (Fig. 1), this being compatible with results of O’Seaghdha et
al (2011) [31]. Additionally, Freedman et al (2011) found that
homozygotes for MYH9 E1 haplotype are protected from Diabetic
Nephropathy when predisposed by FRMD3 SNPs; this is in
contrast to the non-carriers of MYH9 E1 that are prone to
Diabetic Nephropathy when carrying the FRMD3 SNPs. These
data are indicative of more complex and unpredictable gene
interactions and are supportive of our results, signifying the genetic
modifying influence of MYH9 SNPs. Non-coding SNPs on MYH9
may have an unknown effect on MYH9 e.g. in its expression, even
though we did not find such an effect by a quantitative real time
PCR approach. Some of those SNPs may affect proper splicing of
MYH9, as Nelson et al (2010) found recently for rs2413396 and
rs4821480 [32].
Our finding for rs11089788 may prove useful in FH cases, with
early and effective interventions at early life, before symptoms
worsen. However, it remains unclear how certain non-coding
MYH9 variants exert their epistatic role and are associated with
renal failure. It does not escape our attention that despite the
unique character of our cohorts as regards the reduced genetic
complexity owing to the extensive founder mutations, the overall
size of our patient cohorts is somewhat small, and unfortunately
there is no easy way to remedy this inherent limitation of the
population we serve. Future collaboration of multiple research
centers will be necessary to increase the statistical power and
replicate or annul our results.
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